EndPaRL: End-on Versus Parallel Radiofrequency Lesioning for Neurotomy of the Cervical Medial Branch Nerves

Sponsor
University Health Network, Toronto (Other)
Overall Status
Recruiting
CT.gov ID
NCT05818774
Collaborator
(none)
72
1
2
23.7
3

Study Details

Study Description

Brief Summary

Aim of the EndPaRL study is to compare the efficacy and effectiveness of the two techniques utilizing sharp straight conventional radiofrequency needle with a trident needle for radiofrequency neurotomy of Cervical Medial Branch Nerves (CMBNs), in patients presenting with chronic, moderate-to-severe, neck pain due to cervical zygapophyseal joint osteoarthritis, as diagnosed by positive responses to two consecutive diagnostic blocks with local anesthetic of the CMBN.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with parallel lesioning
  • Procedure: Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with end-on lesioning with multitined trident cannulae
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
72 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Prospective, Randomized, Double Blind Clinical Trial Comparing End-on Versus Parallel Radiofrequency Lesioning for Neurotomy of the Cervical Medial Branch Nerves: The EndPaRL Study
Actual Study Start Date :
Mar 10, 2023
Anticipated Primary Completion Date :
Nov 1, 2024
Anticipated Study Completion Date :
Mar 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: RFN of CMBNn with end-on lesioning with multitIned trident cannulae

Intervention type: RF nerve end-on lesioning at 80-850 Celsius for 90 seconds Intervention name: End-on placement of the multitined trident cannulae Intervention description: Patient in lateral position, targeting joint position between the inferior C2 and superior C3 facets, the middle of the facet pillars for the third to fifth cervical levels, and the superior part of the sixth and seventh cervical facets

Procedure: Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with end-on lesioning with multitined trident cannulae
Intervention type: RF nerve lesioning lesioning at 80-850 Celsius for 90 seconds Intervention name: End-on placement of the multitined trident cannulae Intervention description: Patient in lateral position, targeting joint position between the inferior C2 and superior C3 facets, the middle of the facet pillars for the third to fifth cervical levels, and the superior part of the sixth and seventh cervical facets.

Active Comparator: RFN of CMBNn with parallel lesioning with sharp straight conventional cannulae (SIS's technique)

Intervention type: RF nerve parallel lesioning at 80-850 Celsius for 90 seconds Intervention name: Straight sharp conventional (SIS's technique) Intervention description: Technique as described in the SIS Practice Guidelines for parallel lesioning cannulae placement

Procedure: Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with parallel lesioning
Intervention type: RF nerve lesioning at 80-85 degree Celsius for 90 seconds Intervention name: Straight sharp conventional (SIS's technique) Intervention description: Technique as described in the SIS Practice Guidelines for parallel lesioning cannulae placement

Outcome Measures

Primary Outcome Measures

  1. Difference in mean Numerical Rating Scale (NRS) for pain scores [3 months]

    Difference in the mean pain scores before and after procedure. Scale from 0 to 10, where higher scores mean worse outcome

  2. Proportion of patients with positive analgesic response [3 months]

    Proportion of patients with positive analgesic response (≥50% reduction in the NRS score for neck pain compared to baseline)

Secondary Outcome Measures

  1. Difference in the mean Numerical Rating Scale (NRS) for pain scores [at 6 and 12 months]

    Difference in mean NRS for pain scores at 6 and 12 months after the RFA procedure. Scale from 0 to 10, where higher scores mean worse outcome

  2. Proportion of patients with positive analgesic response [at 6 and 12 months]

    Proportion of patients with positive analgesic response (≥50% reduction in the NRS score for neck pain compared to baseline) at 6 & 12 months

  3. Proportion of patients with reduction in the Neck Disability Index (NDI) score [at 3, 6, and 12 months]

    Proportion of patients with ≥10% reduction in the NDI score at 3, 6, and 12 months. Scale from 0 to 50, where higher scores mean worse outcome

  4. Proportion of participants reporting improvement in the Patient Global Impression of Change (PGIC) scale [at 3, 6, and 12 months]

    PGIC score is a 7 point scale depicting a patient's subjective rating of overall improvement over time, as proportion of participants reporting improvement in the PGIC scale at 3, 6, and 12 months

  5. Difference in mean Pittsburgh Sleep Quality Index (PSQI) scores for sleep quality [at 3, 6, and 12 months]

    Difference in mean PSQI scores scores at 3, 6, and 12 months. It has a range of 0-21; higher scores indicate worse sleep quality.

  6. Difference in mean European Quality of Life (EQ-5D-5L score), a self-assessed, health related, quality of life questionnaire. It ranges from 5 to 25, where higher scores indicate worse outcome. [at 3, 6, and 12 months]

    Difference in mean EQ-5D-5L scores at 3, 6, and 12 months

  7. Differences in duration of procedure between 2 groups [day of procedure]

    Differences in duration of procedure in two groups

  8. Differences in discomfort procedure between 2 groups [day of procedure]

    Differences in patient discomfort of procedure

  9. Differences in radiation dose of procedure between 2 groups [day of procedure]

    Differences in radiation dose of procedure

  10. Differences in cost of procedure between 2 groups [day of procedure]

    Differences in cost of the procedures

  11. Difference in opioid requirements in daily oral morphine equivalents between the groups [at 3, 6, and 12 months follow-ups after the procedure]

    Difference in opioid requirements in daily oral morphine equivalents in mg averaged over the 1 week before and at 3, 6, and 12 months follow-ups after the procedure

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Adult patient of either gender aged 18-85 years

  2. Predominant axial (non-radicular) neck pain for at least 3 months

  3. 7-day average NRS score for neck pain ≥ 5/10 at baseline evaluation

  4. Moderate or greater functional impairment due to pain, defined as NDI Questionnaire raw score of 15 out of 50 (≥30%

  5. Cervical spine imaging compatible with Pathria's grade 3 or grade 4 zygapophyseal joint osteoarthritis

  6. Failure to respond to conservative medical management (pharmacologic, physical therapy) for at least 3 months;

  7. Positive response to two consecutive diagnostic blocks of the CMBN with a short and long-acting anesthetic

Exclusion Criteria:
  1. Participants with financial incentives or litigation associated with ongoing pain

  2. Inability to complete assessment instruments

  3. Chronic widespread pain

  4. Prior RFN of the CMBN;

  5. Severe mental health issues

  6. Pregnancy or other reason that precludes the use of fluoroscopy

  7. Untreated coagulopathy

  8. Systemic or local infection at the time of screening.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Health Network (UHN) Toronto Ontario Canada M5T 2S8

Sponsors and Collaborators

  • University Health Network, Toronto

Investigators

  • Principal Investigator: Anuj Bhatia, MD, PhD, Department of Anesthesia and Pain Management, University Health Network, Toronto

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Anuj Bhatia, Associate Professor, University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT05818774
Other Study ID Numbers:
  • 22-5634
First Posted:
Apr 19, 2023
Last Update Posted:
Apr 20, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Anuj Bhatia, Associate Professor, University Health Network, Toronto
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 20, 2023